Everolimus plus exemestane as first-line therapy in [HR.sup.+], [HER2.sup.-] advanced breast cancer in BOLERO-2

The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive ([...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Breast cancer research and treatment 2014-02, Vol.143 (3), p.459
Hauptverfasser:	Masuda, Norikazu, Hortobagyi, Gabriel N, Douma, Shyanne, Geberth, Matthias, Brechenmacher, Thomas, Dakhil, Shaker, Melichar, Bohuslav, Piccart, Martine, Deleu, Ines, Nunzi, Martina, Heng, Daniel Y.C, Campone, Mario, Lebrun, Fabienne, Hart, Lowell, Beck, J. Thaddeus, Hashimy, Mona El, Ringeisen, Francois, Rugo, Hope S, Pistilli, Barbara
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Angiogenesis inhibitors Breast cancer Care and treatment Postmenopausal women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!